Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The new WHO classification of gastrointestinal neuroendocrine tumors and immunohistochemical expression of somatostatin receptor 2 and 5
Oana Popa, Sorina Tãban, Stelian Pantea, et al.
Experimental and Therapeutic Medicine (2021) Vol. 22, Iss. 4
Open Access | Times Cited: 57

Showing 1-25 of 57 citing articles:

Impact of Delayed Surgery on Local Colorectal Neuroendocrine Tumors: Is Surveillance a Feasible Option?
Benjamin C. Greenspun, Daniel Aryeh Metzger, Amanda Foshag, et al.
Annals of Surgical Oncology (2025)
Closed Access | Times Cited: 2
Somatostatin receptor 2 (SSTR2) expression is associated with better clinical outcome and prognosis in rectal neuroendocrine tumors
Joo Young Kim, Jisup Kim, Yong-il Kim, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 14
“Cold” Somatostatin Analogs in Neuroendocrine Neoplasms: Decoding Mechanisms, Overcoming Resistance, and Shaping the Future of Therapy
Sara Massironi, Manuela Albertelli, Iderina Hasballa, et al.
Cells (2025) Vol. 14, Iss. 4, pp. 245-245
Open Access | Times Cited: 1
Role of Somatostatin Signalling in Neuroendocrine Tumours
Olesja Rogoza, Kaspars Megnis, Marija Kudrjavceva, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 3, pp. 1447-1447
Open Access | Times Cited: 34
Phase II study of pembrolizumab and lenvatinib in advanced well-differentiated neuroendocrine tumors
Taymeyah Al‐Toubah, Michael J. Schell, Brian Morse, et al.
ESMO Open (2024) Vol. 9, Iss. 4, pp. 102386-102386
Open Access | Times Cited: 7
Tumour Heterogeneity and the Consequent Practical Challenges in the Management of Gastroenteropancreatic Neuroendocrine Neoplasms
Isabella Reccia, Madhava Pai, Kumar Jayant, et al.
Cancers (2023) Vol. 15, Iss. 6, pp. 1861-1861
Open Access | Times Cited: 15
PET Beyond FDG: New Era of Oncologic Molecular Targets Using Positron-Emitting Radiotracers
Alex Heglin, Bradley Girod, Asha Kandathil
Seminars in Roentgenology (2025)
Closed Access
Endoscopic Treatment of Gastric Neuroendocrine Tumors: What’s Next?
Ilsoo Kim, Yu Kyung Cho
Gut and Liver (2025) Vol. 19, Iss. 2, pp. 148-150
Open Access
Safety of Everolimus in Lung Transplant Recipients Undergoing Surveillance Bronchoscopy with Transbronchial Forceps Biopsy and Cryobiopsy: A Retrospective Cohort Study.
René Hage, Carolin Steinack, Fabrizio Pumo, et al.
Experimental and Clinical Transplantation (2025) Vol. 23, Iss. 2
Closed Access
Clinical characteristics and treatment patterns of patients with gastroenteropancreatic neuroendocrine neoplasia in Germany receiving peptide receptor radionuclide therapy: A real-world data registry-based study
Claus von Hessert-Vaudoncourt, Sebastian Maasberg, Nehara Begum, et al.
Medicine (2025) Vol. 104, Iss. 11, pp. e41853-e41853
Open Access
NET
Kaique Ferreira Costa de Almeida, Fernanda Maris Peria
Elsevier eBooks (2025), pp. 649-663
Closed Access
Genetic insight into lung neuroendocrine tumors: Notch and Wnt signaling pathways as potential targets
Giulia Pecora, Camilla Mancini, Rossella Mazzilli, et al.
Journal of Translational Medicine (2025) Vol. 23, Iss. 1
Open Access
Correlation of Somatostatin Receptor 2 Expression, 68Ga-DOTATATE PET Scan and Octreotide Treatment in Thymic Epithelial Tumors
Anja C. Roden, Sagar Rakshit, Geoffrey B. Johnson, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 15
New insights in diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms
Feng Yin, Zihao Wu, Jinping Lai
World Journal of Gastroenterology (2022) Vol. 28, Iss. 17, pp. 1751-1767
Open Access | Times Cited: 14
Optimising Outcomes and Surveillance Strategies of Rectal Neuroendocrine Neoplasms
Rajaventhan Srirajaskanthan, Dominique Clement, Sarah Brown, et al.
Cancers (2023) Vol. 15, Iss. 10, pp. 2766-2766
Open Access | Times Cited: 7
Prevalence of Endocrine Manifestations and GIST in 108 Systematically Screened Patients With Neurofibromatosis Type 1
H. Dupuis, Benjamin Chevalier, Catherine Cardot-Bauters, et al.
Journal of the Endocrine Society (2023) Vol. 7, Iss. 8
Open Access | Times Cited: 7
A new schedule of one week on/one week off temozolomide as second-line treatment of advanced neuroendocrine carcinomas (TENEC-TRIAL): a multicenter, open-label, single-arm, phase II trial
Claudia von Arx, Giuseppina Della Vittoria Scarpati, L. Cannella, et al.
ESMO Open (2024) Vol. 9, Iss. 5, pp. 103003-103003
Open Access | Times Cited: 2
Surgical aspects of small intestinal neuroendocrine tumors
Amram Kupietzky, Roi Dover, Haggi Mazeh
World Journal of Gastrointestinal Surgery (2023) Vol. 15, Iss. 4, pp. 566-577
Open Access | Times Cited: 6
Is There a Role for Surgical Resection of Grade 3 Neuroendocrine Neoplasms?
Luis C. Borbon, Catherine G. Tran, Scott K. Sherman, et al.
Annals of Surgical Oncology (2022) Vol. 29, Iss. 11, pp. 6936-6946
Open Access | Times Cited: 10
The Role of Receptor–Ligand Interaction in Somatostatin Signaling Pathways: Implications for Neuroendocrine Tumors
Agnieszka Milewska-Kranc, Jarosław B. Ćwikła, Agnieszka Kolasińska-Ćwikła
Cancers (2023) Vol. 16, Iss. 1, pp. 116-116
Open Access | Times Cited: 5
The New Radiolabeled Peptide 99mTcEDDA/HYNIC-TOC: Is It a Feasible Choice for Diagnosing Gastroenteropancreatic NETs?
Mirela Gherghe, Alexandra Maria Lazăr, A Stanciu, et al.
Cancers (2022) Vol. 14, Iss. 11, pp. 2725-2725
Open Access | Times Cited: 9
Neuroendocrine Neoplasms
Ajitha Ramesh, Aniruddha Chatterjee, Rathan M. Subramaniam
PET Clinics (2023) Vol. 18, Iss. 2, pp. 161-168
Closed Access | Times Cited: 5
Prolonged Response to Dabrafenib/Trametinib in Grade 3 Metastatic Pancreatic Neuroendocrine Tumor (NET G3) with BRAF V600E Mutation
Benjamin E. Ueberroth, Christopher H. Lieu, Robert W. Lentz
Journal of Gastrointestinal Cancer (2024) Vol. 55, Iss. 3, pp. 1448-1452
Open Access | Times Cited: 1
An Update on the Management of Rectal Neuroendocrine Neoplasms
Aviva Frydman, Raj Srirajaskanthan
Current Treatment Options in Oncology (2024) Vol. 25, Iss. 11, pp. 1461-1470
Open Access | Times Cited: 1
Second Primary Malignancies in Patients with a Neuroendocrine Neoplasm in England
Beth Russell, Benjamin White, Brian Rous, et al.
Neuroendocrinology (2023) Vol. 113, Iss. 8, pp. 811-821
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top